A detailed history of Palisade Capital Management LLC transactions in Castle Biosciences Inc stock. As of the latest transaction made, Palisade Capital Management LLC holds 502,317 shares of CSTL stock, worth $13.6 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
502,317
Previous 537,974 6.63%
Holding current value
$13.6 Million
Previous $11.7 Million 22.33%
% of portfolio
0.45%
Previous 0.37%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.4 - $31.47 $620,431 - $1.12 Million
-35,657 Reduced 6.63%
502,317 $14.3 Million
Q2 2024

Aug 14, 2024

SELL
$18.84 - $24.94 $173,196 - $229,273
-9,193 Reduced 1.68%
537,974 $11.7 Million
Q1 2024

May 15, 2024

BUY
$18.06 - $25.3 $145,057 - $203,209
8,032 Added 1.49%
547,167 $12.1 Million
Q4 2023

Feb 14, 2024

SELL
$12.19 - $22.43 $769,505 - $1.42 Million
-63,126 Reduced 10.48%
539,135 $11.6 Million
Q3 2023

Nov 14, 2023

BUY
$13.28 - $20.3 $756 - $1,157
57 Added 0.01%
602,261 $10.2 Million
Q2 2023

Aug 14, 2023

BUY
$11.66 - $26.0 $293,668 - $654,836
25,186 Added 4.36%
602,204 $8.26 Million
Q1 2023

May 08, 2023

BUY
$19.47 - $28.49 $504,720 - $738,546
25,923 Added 4.7%
577,018 $13.1 Million
Q4 2022

Feb 14, 2023

SELL
$18.08 - $30.0 $521,589 - $865,470
-28,849 Reduced 4.97%
551,095 $13 Million
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $22,757 - $34,697
1,011 Added 0.17%
579,944 $15.1 Million
Q2 2022

Aug 10, 2022

BUY
$16.0 - $45.99 $2.72 Million - $7.8 Million
169,701 Added 41.47%
578,933 $12.7 Million
Q1 2022

May 09, 2022

BUY
$33.17 - $46.98 $1.88 Million - $2.67 Million
56,791 Added 16.11%
409,232 $18.4 Million
Q4 2021

Feb 10, 2022

BUY
$39.06 - $67.58 $13.8 Million - $23.8 Million
352,441 New
352,441 $15.1 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $713M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Palisade Capital Management LLC Portfolio

Follow Palisade Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Palisade Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Palisade Capital Management LLC with notifications on news.